HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use ROPIVACAINE HYDROCHLORIDE safely and effectively. See full prescribing information for ROPIVACAINE HYDROCHLORIDE. ROPIVACAINE HYDROCHLORIDE injection, for epidural, perineural, or infiltration use Initial U.S. Approval: 1996 INDICATIONS AND USAGERopivacaine hydrochloride is an amide local anesthetic indicated in adults for the production of local or regional anesthesia for surgery and for acute pain management. (1) Surgical Anesthesia: epidural block for surgery including cesarean section; major nerve block; local infiltration. (1) Acute Pain Management: epidural continuous infusion or intermittent bolus, e.g., postoperative or labor; local infiltration. (1) DOSAGE AND ADMINISTRATIONDOSAGE FORMS AND STRENGTHSInjection: 2 mg/mL (0.2%), 5 mg/mL (0.5%), 7.5 mg/mL (0.75%) or 10 mg/mL (1%) in single-dose vials. (3) CONTRAINDICATIONSHistory of hypersensitivity to local anesthetics of the amide-type. (4) WARNINGS AND PRECAUTIONS- •
- Delay in proper management of dose-related toxicity, underventilation, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest and, possibly, death. (5.1)
- •
- In performing ropivacaine hydrochloride blocks, unintended intravenous injection is possible and may result in cardiac arrhythmia or cardia arrest. (5.2)
- •
- Intra-articular infusions of local anesthetics may cause chondrolysis. Ropivacaine hydrochloride is not approved for this use. (5.3)
- •
- Signs of methemoglobinemia may occur. (5.4)
ADVERSE REACTIONSMost common adverse reactions (incidence ≥5%) are hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain. (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1‑800‑438‑1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS- •
- Agents structurally related to amide-type local anesthetics: Concurrent use may cause additive effects. (7)
See 17 for PATIENT COUNSELING INFORMATION. Revised: 10/2023 |